Logo
x

Search

Subscribe Now

Coherus

Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry

Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry

  • June 28, 2024
Coherus Highlights Results from the P-II Study of Casdozokitug for Advanced or Metastatic Hepatocellular Carcinoma (uHCC)

Coherus Highlights Results from the P-II Study of Casdozokitug for Advanced or Metastatic Hepatocellular Carcinoma (uHCC)

  • January 19, 2024
Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)

Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (N...

  • October 31, 2023
Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount

  • July 3, 2023
Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

Coherus Receives the US FDA’s Approval of Udenyca (biosimilar, pegfilgrastim) for Febrile Neutropenia

  • March 7, 2023
Coherus and Junshi Biosciences Report P-III Trial (JUPITER-02) Results of Toripalimab for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus and Junshi Biosciences Report P-III Trial (JUPITER-02) Results of Toripalimab for Recurrent or Metastatic Nasopharyngeal C...

  • February 16, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.